Valion Bio, Inc. (VBIO) has become one of the more extreme stories in the micro-cap biotechnology space. At the latest available close, shares traded near $0.17, down roughly 97% from their 52-week high of $5.60. That collapse has shifted investor attention to a widely searched question: can VBIO get back to $1.00?
$1.00 is more than a round number for this stock. It is the threshold most commonly associated with Nasdaq's minimum bid price listing standard, and it sits near VBIO's 200-day moving average of roughly $1.10. The stock's 52-week range of approximately $0.16 to $5.60 shows that prices above $1 were reachable relatively recently, which keeps the question alive even after the sharp decline. For a sub-$1 stock, reclaiming $1 would also represent a psychological shift out of "penny stock" territory, potentially improving visibility and institutional accessibility.
Valion Bio, Inc. is a late-stage biopharmaceutical company formerly known as Tivic Health Systems, Inc.; it changed its name and ticker in April 2026. Its lead candidate, Entolimod, is a Toll-like receptor 5 (TLR5) agonist in late-stage development for acute radiation syndrome (ARS). The program is being advanced under the FDA's Animal Rule pathway, which permits approval based on animal efficacy data when human clinical trials are not feasible. The company is also pursuing oncology supportive care indications and owns Velocity Bioworks, a contract development and manufacturing organization (CDMO).
The latest verified close put VBIO at $0.1708, with after-hours quotes near $0.17 as U.S. markets remained closed. The company's market capitalization was recently quoted below $1 million, and the stock has been extremely volatile. Financial data show a trailing twelve-month net loss of roughly $13 million, total cash of about $7.2 million, and total debt of about $17.0 million. The most recent book value per share was approximately $3.84, though deeply loss-making micro-cap biotechs rarely trade on book value alone. The 50-day moving average sits near $0.46, reinforcing the scale of the decline from levels that prevailed only weeks ago.
The core bull case is that Entolimod becomes a government-funded medical countermeasure. Valion Bio has described engagement with U.S. agencies including the Biomedical Advanced Research and Development Authority (BARDA), the Defense Threat Reduction Agency (DTRA), and the National Institute of Allergy and Infectious Diseases (NIAID), as well as an international request for information from Ukraine's Ministry of Health. A procurement contract for the U.S. Strategic National Stockpile would be the most important single catalyst; the company has characterized the opportunity as potentially nine-figure and non-dilutive. Additional support could come from CDMO revenue at Velocity Bioworks and clinical progress in chemotherapy-induced neutropenia.
The obstacles are substantial. No government procurement contract has been announced, and regulatory milestones remain unproven. The company is burning cash, carries meaningful debt, and will likely need additional capital before any commercial inflection arrives, creating dilution risk for current shareholders. Nasdaq listing compliance is another concern for a stock trading well below $1. Visible third-party analyst coverage is extremely thin, and the most prominent aggregated rating has been a sell, meaning the $1 case is currently driven by event speculation and technical psychology rather than published analyst support.
The most important support zone is the 52-week low near $0.16. Below that, there is little established price history. On the upside, the first meaningful supply zone appears around $0.46 to $0.51, near the 50-day moving average and recent consolidation levels. The decisive test remains $1.00, which aligns with the 200-day moving average and the psychological round-number level. A sustained move toward $1 would require the stock to first reclaim and hold the $0.46–$0.51 area, confirming that the long-term downtrend has reversed.
For traders monitoring volatile situations like VBIO, AI Daily Buy/Sell Signals from Tickeron uses artificial intelligence to continuously scan thousands of stocks and ETFs and generate Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. The tool is designed to help traders discover opportunities, monitor existing positions, and identify shifting market trends more efficiently than manual screening. While no signal system can predict binary biotech outcomes, combining AI-generated technical signals with event-driven research may help traders respond more quickly when conditions change.
A return to $1.00 appears possible only under a specific, catalyst-heavy scenario: a government stockpile contract or equivalent revenue event, successful regulatory progress for Entolimod, and financing that does not excessively dilute current holders. The strongest supporting factors are the national-security relevance of the lead program and the company's CDMO infrastructure. The primary risks are equally clear: no contract has been signed, losses continue, debt is elevated, and the stock remains in a steep downtrend. Investors should monitor government procurement announcements, cash position and dilution, Nasdaq listing status, and whether VBIO can reclaim the $0.46–$0.51 zone as a first technical step toward any sustainable recovery toward $1.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor tells us that VBIO and SNGX have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that VBIO and SNGX's prices will move in lockstep.
| Ticker / NAME | Correlation To VBIO | 1D Price Change % | ||
|---|---|---|---|---|
| VBIO | 100% | +0.41% | ||
| SNGX - VBIO | 27% Poorly correlated | +5.50% | ||
| ATOS - VBIO | 26% Poorly correlated | -1.93% | ||
| DARE - VBIO | 25% Poorly correlated | +1.32% | ||
| IBIO - VBIO | 24% Poorly correlated | -2.72% | ||
| ENLV - VBIO | 23% Poorly correlated | -2.00% | ||
More | ||||